The Evolution of Antifungal Therapy: Traditional Agents, Current Challenges and Future Perspectives

Overview

Journal Curr Res Microb Sci

Date 2025 Feb 3

PMID 39897698

Authors

Cassia Milena de Souza

Barbara Tavares Bezerra

Daniel Agreda Mellon

Haroldo Cesar de Oliveira

Affiliations

Soon will be listed here.

Abstract

Fungal infections kill more than 3 million people every year. This high number reflects the significant challenges that treating these diseases worldwide presents. The current arsenal of antifungal drugs is limited and often accompanied by high toxicity to patients, elevated treatment costs, increased frequency of resistance rates, and the emergence of naturally resistant species. These treatment challenges highlight the urgency of developing new antifungal therapies, which could positively impact millions of lives each year globally. Our review offers an overview of the antifungal drugs currently available for treatment, presents the status of new antifungal drugs under clinical study, and explores ahead to future candidates that aim to help address this important global health issue.

References

Almajid A, Bazroon A, Al-Awami H, Albarbari H, Alqahtani I, Almutairi R . Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials. Cureus. 2024; 16(4):e59210. PMC: 11131969. DOI: 10.7759/cureus.59210. View

Toth Z, Forgacs L, Locke J, Kardos G, Nagy F, Kovacs R . In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae. J Antimicrob Chemother. 2019; 74(12):3505-3510. PMC: 6857195. DOI: 10.1093/jac/dkz390. View

Petraitis V, Petraitiene R, McCarthy M, Kovanda L, Zaw M, Hussain K . Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2017; 61(9). PMC: 5571280. DOI: 10.1128/AAC.00305-17. View

Badali H, Canete-Gibas C, Patterson H, Sanders C, Mermella B, Garcia V . In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes. Mycoses. 2021; 64(7):748-752. DOI: 10.1111/myc.13273. View

Hoenigl M, Seidel D, Carvalho A, Rudramurthy S, Arastehfar A, Gangneux J . The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022; 3(7):e543-e552. PMC: 8789240. DOI: 10.1016/S2666-5247(21)00237-8. View

Cornely O, Ostermann H, Koehler P, Teschner D, Limburg E, Kramer W . Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. J Antimicrob Chemother. 2023; 78(11):2645-2652. PMC: 10631825. DOI: 10.1093/jac/dkad269. View

Angulo D, Alexander B, Rautemaa-Richardson R, Alastruey-Izquierdo A, Hoenigl M, Ibrahim A . Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections. J Fungi (Basel). 2022; 8(11). PMC: 9695964. DOI: 10.3390/jof8111121. View

Wang Z, Wang G . APD: the Antimicrobial Peptide Database. Nucleic Acids Res. 2003; 32(Database issue):D590-2. PMC: 308759. DOI: 10.1093/nar/gkh025. View

Wakharde A, Halbandge S, Phule D, Karuppayil S . Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets. Assay Drug Dev Technol. 2018; 16(5):232-246. DOI: 10.1089/adt.2017.826. View

10.

Palmeira V, Kneipp L, Rozental S, Alviano C, Santos A . Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence. PLoS One. 2008; 3(10):e3382. PMC: 2557140. DOI: 10.1371/journal.pone.0003382. View

11.

Cavassin F, Bau-Carneiro J, Vilas-Boas R, Queiroz-Telles F . Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infect Dis Ther. 2021; 10(1):115-147. PMC: 7954977. DOI: 10.1007/s40121-020-00382-7. View

12.

Rudkin F, Raziunaite I, Workman H, Essono S, Belmonte R, MacCallum D . Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis. Nat Commun. 2018; 9(1):5288. PMC: 6290022. DOI: 10.1038/s41467-018-07738-1. View

13.

Freitas C, Felipe M . Candida albicans and Antifungal Peptides. Infect Dis Ther. 2023; 12(12):2631-2648. PMC: 10746669. DOI: 10.1007/s40121-023-00889-9. View

14.

Pappas P, Vazquez J, Oren I, Rahav G, Aoun M, Bulpa P . Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. J Antimicrob Chemother. 2023; 78(10):2471-2480. PMC: 10545531. DOI: 10.1093/jac/dkad256. View

15.

Petraitis V, Petraitiene R, Katragkou A, Maung B, Naing E, Kavaliauskas P . Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2020; 64(6). PMC: 7269506. DOI: 10.1128/AAC.02429-19. View

16.

Zhang D, Liao W, Chen C, Lai H, Liu S . Terbinafine Hydrochloride Combined With Itraconazole for Fungal Skin Diseases: A Randomized Controlled Trial. Am J Ther. 2021; 28(2):e179-e186. DOI: 10.1097/MJT.0000000000001075. View

17.

Denning D . Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024; 24(7):e428-e438. DOI: 10.1016/S1473-3099(23)00692-8. View

18.

Trevino-Rangel R, Villanueva-Lozano H, Hernandez-Rodriguez P, Martinez-Resendez M, Garcia-Juarez J, Rodriguez-Rocha H . Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays. Med Mycol. 2015; 54(3):280-6. DOI: 10.1093/mmy/myv109. View

19.

Spec A, Pullman J, Thompson G, Powderly W, Tobin E, Vazquez J . MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 2019; 74(10):3056-3062. DOI: 10.1093/jac/dkz277. View

20.

Samaranayake L, Leung W, Jin L . Oral mucosal fungal infections. Periodontol 2000. 2009; 49:39-59. DOI: 10.1111/j.1600-0757.2008.00291.x. View